 | • レポートコード：MRC2302E0133 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、223ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に589.1億ドルであった世界のバイオ医薬品CMO＆CRO市場規模が、2022年に691.8億ドルになり、2027年まで年平均17.68%で成長して1565億ドルに達すると予測しています。本レポートでは、バイオ医薬品CMO＆CROの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、供給元別（哺乳類、非哺乳類）分析、サービス種類別（受託製造、受託研究）分析、製品別（生物製剤、バイオシミラー）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、AbbVie, Inc.、Baxter International Inc.、Binex Co., Ltd.、Biomeva GmbH、Boehringer Ingelheim GmbH、Catalent, Inc.、Charles River Laboratories International, Inc、CMC Biologics A/S、FUJIFILM Diosynth Biotechnologies U.S.A., Inc.、ICON plc.、Inno Biologics Sdn Bhd、などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のバイオ医薬品CMO＆CRO市場規模：供給元別 - 哺乳類由来バイオ医薬品の市場規模 - 非哺乳類由来バイオ医薬品の市場規模 ・世界のバイオ医薬品CMO＆CRO市場規模：サービス種類別 - 受託製造サービスの市場規模 - 受託研究サービスの市場規模 ・世界のバイオ医薬品CMO＆CRO市場規模：製品別 - 生物製剤の市場規模 - バイオシミラーの市場規模 ・世界のバイオ医薬品CMO＆CRO市場規模：地域別 - 南北アメリカのバイオ医薬品CMO＆CRO市場規模 アメリカのバイオ医薬品CMO＆CRO市場規模 カナダのバイオ医薬品CMO＆CRO市場規模 ブラジルのバイオ医薬品CMO＆CRO市場規模 ... - アジア太平洋のバイオ医薬品CMO＆CRO市場規模 日本のバイオ医薬品CMO＆CRO市場規模 中国のバイオ医薬品CMO＆CRO市場規模 インドのバイオ医薬品CMO＆CRO市場規模 韓国のバイオ医薬品CMO＆CRO市場規模 台湾のバイオ医薬品CMO＆CRO市場規模 ... -ヨーロッパ/中東/アフリカのバイオ医薬品CMO＆CRO市場規模 イギリスのバイオ医薬品CMO＆CRO市場規模 ドイツのバイオ医薬品CMO＆CRO市場規模 フランスのバイオ医薬品CMO＆CRO市場規模 ロシアのバイオ医薬品CMO＆CRO市場規模 ... -その他地域のバイオ医薬品CMO＆CRO市場規模 ・競争状況 ・企業情報 |
The Global Biopharmaceutical CMO & CRO Market size was estimated at USD 58.91 billion in 2021 and expected to reach USD 69.18 billion in 2022, and is projected to grow at a CAGR 17.68% to reach USD 156.50 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biopharmaceutical CMO & CRO to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Source, the market was studied across Mammalian and Non-Mammalian.
Based on Service Type, the market was studied across Contract Manufacturing and Contract Research.
Based on Product, the market was studied across Biologics and Biosimilars.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biopharmaceutical CMO & CRO market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopharmaceutical CMO & CRO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopharmaceutical CMO & CRO Market, including AbbVie, Inc., Baxter International Inc., Binex Co., Ltd., Biomeva GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc, CMC Biologics A/S, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., Inno Biologics Sdn Bhd, JRS PHARMA GmbH & Co. KG., Laboratory Corporation of America Holdings, Lonza Group AG, Patheon Inc., Pfizer Inc., ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics, Toyobo Co., Ltd., and wuxi biologics cayman inc.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biopharmaceutical CMO & CRO Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopharmaceutical CMO & CRO Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopharmaceutical CMO & CRO Market?
4. What is the competitive strategic window for opportunities in the Global Biopharmaceutical CMO & CRO Market?
5. What are the technology trends and regulatory frameworks in the Global Biopharmaceutical CMO & CRO Market?
6. What is the market share of the leading vendors in the Global Biopharmaceutical CMO & CRO Market?
7. What modes and strategic moves are considered suitable for entering the Global Biopharmaceutical CMO & CRO Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
5.1.1.2. Potential demand for macromolecular therapeutics
5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
5.1.2. Restraints
5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
5.1.3. Opportunities
5.1.3.1. Penetration of advanced technology in the biotechnology field
5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
5.1.4. Challenges
5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
5.2. Cumulative Impact of COVID-19
6. Biopharmaceutical CMO & CRO Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Non-Mammalian
7. Biopharmaceutical CMO & CRO Market, by Service Type
7.1. Introduction
7.2. Contract Manufacturing
7.3. Contract Research
8. Biopharmaceutical CMO & CRO Market, by Product
8.1. Introduction
8.2. Biologics
8.3. Biosimilars
9. Americas Biopharmaceutical CMO & CRO Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biopharmaceutical CMO & CRO Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Baxter International Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Binex Co., Ltd.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Biomeva GmbH
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Boehringer Ingelheim GmbH
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Catalent, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Charles River Laboratories International, Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. CMC Biologics A/S
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. ICON plc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Inno Biologics Sdn Bhd
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. JRS PHARMA GmbH & Co. KG.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Laboratory Corporation of America Holdings
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Lonza Group AG
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Patheon Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Pfizer Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. ProBioGen AG
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Rentschler Biopharma SE
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Samsung Biologics
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Toyobo Co., Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. wuxi biologics cayman inc
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing